Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $17.2352W HIGH $30.55
Volume
12.05 K
Value Traded
22.51 M
Short % Float
5.47%
Days to Cover
5.8
+2.69%Week
+14.25%1 Month
+13.6%3 Month
+33.07%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.41 B
EPS (TTM)
1.85
P/E Ratio
16.14
Ent. Value
2.00 B
Total Shares
81.25 M
Float Shares
79.96 M
Insiders
1.59%
Institutions
103.84%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
MD Catalyst Timeline
Dated clinical, regulatory and corporate events for Pediatrix Medical Group, Inc.
Past FDA Catalysts and PDUFA Decisions
How MD actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 83%
Small Cap(rank 560 of 674)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every MD program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| McEachin ThomasDirector | Disposition | -11,427 7,196 held | $0.00 | 05/13/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MD
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in MD for Q2 2026. | ||||
Ownership Trends
MD Short Interest
Shares sold short, counted twice a month.
5.47%
Short % of Float
of tradable shares sold short
4.4M
Shares Sold Short
-5.2% vs prior count
5.8 High
Days to Cover
trading days of normal volume to buy every short share back
750.3K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MD ranks across every disease it competes in
Competitive Position is a premium feature
See how MD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMD News
-MD
Oct 29, 2026Pediatrix Medical Group Reports Third Quarter Results
Pediatrix Medical Group reported its third quarter results. The announcement was made from Fort Lauderdale, Florida, but specific financial figures or insights were not detailed in the release.
Read more →-MD
Oct 20, 2026Pediatrix Medical Group 2026 Third Quarter Conference Call/Webcast Scheduled for Thursday, October 29, 2026
Pediatrix Medical Group has scheduled its 2026 Third Quarter Conference Call/Webcast for October 29, 2026. This event will provide updates and insights into the company's performance and future strategies. Stakeholders are encouraged to attend for detailed information regarding the company's operations.
Read more →-MD
Aug 4, 2026▼ -5.9%on this news
Pediatrix Medical Group Reports Second Quarter Results
Pediatrix Medical Group reported a strong second quarter for 2026, with earnings of $0.49 per share and an adjusted EPS of $0.63. The company experienced a 4.0% increase in net revenue, attributed to recent acquisitions and improved reimbursement metrics. However, patient volume saw a decline of 2.1%, and operational costs rose due to higher salaries and restructuring expenses. Despite these challenges, Pediatrix maintains a robust financial position and reaffirms its full-year outlook for adjusted EBITDA.
Read more →-MD
Jul 15, 2026▲ +7.3%on this news
Pediatrix Medical Group Provides Second Quarter Update
Pediatrix Medical Group, Inc. has provided an update on its second quarter 2026 business trends, confirming that its payor mix has remained stable and unchanged compared to recent historical trends. This announcement comes in light of recent reports from other healthcare market participants regarding shifting utilization and reimbursement trends. The company's position as a leading provider of physician services remains intact.
Read more →-MD
May 5, 2026▼ -7.1%on this news
Pediatrix Medical Group Reports First Quarter Results
Pediatrix Medical Group, Inc. reported its first-quarter earnings for 2026, showing a net revenue of $476 million and a net income of $30 million. The company experienced growth in adjusted earnings per share and EBITDA, exceeding prior expectations. Despite these positive results, the organization faced declines in patient volume and an increase in operating expenses. The company has reaffirmed its annual Adjusted EBITDA guidance for 2026, positioning itself for future opportunities.
Read more →-MD
Feb 23, 2026Pediatrix Medical Group Announces 47th Annual NEO: The Conference for Neonatology
Pediatrix Medical Group will host the 47th annual NEO: The Conference for Neonatology from February 25-27 in Las Vegas. The conference aims to bring together leading experts to discuss advancements and challenges in neonatal-perinatal medicine. With a focus on improving outcomes for newborns, the event will feature interactive sessions and the induction of Dr. Waldemar Carlo into the Legends of Neonatology Hall of Fame.
Read more →-MD
Feb 19, 2026▼ -12.2%on this newsshared move
Pediatrix Medical Group Reports Fourth Quarter Results
Pediatrix Medical Group reported its fourth quarter results for 2025, highlighting earnings of $0.40 per share and an adjusted EBITDA of $66 million. The company experienced a revenue decrease from $502 million to $494 million compared to the previous year, although same-unit revenue grew by 4.0%. The financial results reflect an overall solid performance despite some headwinds in the healthcare industry. The company anticipates a promising 2026 with an expected adjusted EBITDA range of $280 million to $300 million.
Read more →-MD
Nov 3, 2025▲ +24.2%on this news
Pediatrix Medical Group Reports Third Quarter Results Raises Full Year 2025 Adjusted EBITDA Outlook Range
Pediatrix Medical Group reported its third quarter results, revealing earnings of $0.84 per share and a non-GAAP Adjusted EPS of $0.67. The company exceeded its expectations, attributing strong performance to improved collection activity and a favorable payor mix. Despite a decrease in net revenue year-over-year, the outlook for full year 2025 Adjusted EBITDA has been raised to between $270 million and $290 million. However, challenges remain as the company navigates a changing healthcare landscape.
Read more →-MD
Aug 18, 2025Pediatrix Medical Group Announces $250 Million Share Repurchase Program
Pediatrix Medical Group, Inc. has announced a $250 million share repurchase program authorized by its Board of Directors. The initiative stems from the company's strong cash flow and low debt levels, suggesting a solid financial foundation. Management intends to use the program strategically while balancing other investment opportunities. However, the actual execution of the repurchases is contingent on market conditions and can be halted at any moment, introducing an element of uncertainty.
Read more →-MD
Aug 5, 2025▲ +5%on this news· ran to +17% by day 1
Pediatrix Medical Group Reports Second Quarter Results Raises Full Year 2025 Adjusted EBITDA Outlook Range
Pediatrix Medical Group reported strong second quarter results with earnings of $0.46 per share and raised its full-year Adjusted EBITDA outlook to between $245 and $255 million. Despite a decrease in net revenue compared to the previous year, the company experienced growth in same-unit net revenue and reported a net income improvement. The performance is attributed to stable payor mix and strong patient volumes in neonatology services. However, Pediatrix remains cautious regarding future market conditions.
Read more →-MD
Jul 1, 2025Pediatrix Board Appoints Kurt D. Newman, M.D. as Independent Director
Pediatrix Medical Group, Inc. has appointed Kurt D. Newman, M.D. as an independent director effective July 1, 2025. Dr. Newman, a former President and CEO of Children's National Hospital, brings extensive experience in pediatric healthcare and innovation. His commitment to patient-centered care and mental health advocacy highlights the alignment with Pediatrix's mission. The board expresses confidence that Dr. Newman's insights will enhance the company’s strategic direction in upcoming challenges.
Read more →-MD
May 6, 2025▲ +11.8%on this news
Pediatrix Medical Group Reports First Quarter Results Raises Full Year 2025 Adjusted EBITDA Outlook Range
Pediatrix Medical Group reported a strong first quarter performance for 2025, with earnings of $0.24 per share and raising its Adjusted EBITDA outlook for the year to a range of $220 million to $240 million. Despite experiencing a decline in net revenue compared to the previous year, the company saw growth in same-unit revenue and improved payor mix. The results reflect effective cost management and the impact of restructuring initiatives. However, Pediatrix remains cautious due to uncertainties in the healthcare sector.
Read more →-MD
Jan 13, 2025▲ +7%on this news
Pediatrix Announces Strategic Initiatives For Enhanced Shareholder Value Creation
Pediatrix Medical Group, Inc. has announced a leadership transition with Executive Chair Mark S. Ordan returning as Chief Executive Officer. This change aims to enhance shareholder value and strengthen the company's focus on hospital relationships and clinical excellence. The company has initiated several strategic initiatives, including a shift to a hybrid revenue cycle management model and divesting certain clinics. Pediatrix expects to achieve an adjusted EBITDA at the higher end of its 2024 outlook, with upcoming earnings results to be released in February 2025.
Read more →-MD
May 30, 2024Pediatrix Medical Group, Inc. (NYSE:MD) Supplemental Disclosure
Pediatrix Medical Group, Inc. (MD) has provided updates regarding its operational focus and portfolio optimization strategy, highlighting a projected Adjusted EBITDA range of $200 million to $220 million for 2024. The company is set to exit several office-based practices as part of its optimization plans, which it aims to complete by the end of the year. While the changes are expected to enhance operational efficiency, there are inherent risks associated with transitioning to new management processes and external factors affecting performance.
Read more →-MD
Feb 20, 2024▼ -8.9%on this news
FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175, x 5692 charles.lynch@pediatrix.com
Pediatrix Medical Group, Inc. reported a loss from continuing operations of $1.50 per share for the fourth quarter of 2023, reflecting a significant overall downfall with net revenue falling to $496 million. The latest financial results showed a decrease in same-unit revenue, impacted by patient volume and reimbursement factors. Despite implementing a hybrid revenue-cycle management structure and anticipating improved cash flow, the company struggled with a substantial loss and impairment charges. Moving forward, Pediatrix expect fourth quarter Adjusted EBITDA to range between $200 million and $220 million for 2024.
Read more →About Pediatrix Medical Group, Inc.
Headquarters1301 CONCORD TERRACE, SUNRISE, FL, 33323
BIOPHARMAWATCH ELITE PLUS
Trade the next MD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime